BACKGROUND: Several recent studies have shown that neutrophil gelatinase-associated lipocalin (NGAL) may be a promising biomarker for the early detection of acute kidney injury (AKI), but the role of NGAL in predicting adverse clinical outcomes has not been well addressed. The purpose of this study was to evaluate the usefulness of urine NGAL as outcome predictor in patients with AKI. METHODS: This was a prospective cohort study enrolling hospitalized AKI patients. Patients were divided into four groups according to initial urine NGAL excretion quartiles. The primary clinical outcome variables were in-hospital mortality and renal function at 4 weeks. RESULTS: Initial urine NGAL was identified as an independent predictor of in-hospital mortality and persistent loss of renal function. In the analysis of predictive performance of urine NGAL, the AUC was 0.882 and a cutoff value of 298.28 ng/ml predicted loss of renal function with 88.2% sensitivity and 81.0% specificity. CONCLUSION: This study could suggest that urine NGAL, a new early biomarker might also be served as a reliable clinical outcome predictor in AKI patients. 2010 S. Karger AG, Basel.
BACKGROUND: Several recent studies have shown that neutrophil gelatinase-associated lipocalin (NGAL) may be a promising biomarker for the early detection of acute kidney injury (AKI), but the role of NGAL in predicting adverse clinical outcomes has not been well addressed. The purpose of this study was to evaluate the usefulness of urine NGAL as outcome predictor in patients with AKI. METHODS: This was a prospective cohort study enrolling hospitalized AKI patients. Patients were divided into four groups according to initial urine NGAL excretion quartiles. The primary clinical outcome variables were in-hospital mortality and renal function at 4 weeks. RESULTS: Initial urine NGAL was identified as an independent predictor of in-hospital mortality and persistent loss of renal function. In the analysis of predictive performance of urine NGAL, the AUC was 0.882 and a cutoff value of 298.28 ng/ml predicted loss of renal function with 88.2% sensitivity and 81.0% specificity. CONCLUSION: This study could suggest that urine NGAL, a new early biomarker might also be served as a reliable clinical outcome predictor in AKI patients. 2010 S. Karger AG, Basel.
Authors: Jens H Westhoff; Felix S Seibert; Sina Waldherr; Frederic Bauer; Burkhard Tönshoff; Alexander Fichtner; Timm H Westhoff Journal: Eur J Pediatr Date: 2017-04-14 Impact factor: 3.183
Authors: Thomas L Nickolas; Kai M Schmidt-Ott; Pietro Canetta; Catherine Forster; Eugenia Singer; Meghan Sise; Antje Elger; Omar Maarouf; David Antonio Sola-Del Valle; Matthew O'Rourke; Evan Sherman; Peter Lee; Abdallah Geara; Philip Imus; Achuta Guddati; Allison Polland; Wasiq Rahman; Saban Elitok; Nasir Malik; James Giglio; Suzanne El-Sayegh; Prasad Devarajan; Sudarshan Hebbar; Subodh J Saggi; Barry Hahn; Ralph Kettritz; Friedrich C Luft; Jonathan Barasch Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Eugenia Singer; Antje Elger; Saban Elitok; Ralph Kettritz; Thomas L Nickolas; Jonathan Barasch; Friedrich C Luft; Kai M Schmidt-Ott Journal: Kidney Int Date: 2011-03-16 Impact factor: 10.612
Authors: Elizabeth C Verna; Robert S Brown; Erica Farrand; Elsa M Pichardo; Catherine S Forster; David A Sola-Del Valle; Sarah H Adkins; Meghan E Sise; Juan A Oliver; Jai Radhakrishnan; Jonathan M Barasch; Thomas L Nickolas Journal: Dig Dis Sci Date: 2012-05-06 Impact factor: 3.199
Authors: Monica Mannelqvist; Ingunn M Stefansson; Elisabeth Wik; Kanthida Kusonmano; Maria B Raeder; Anne M Øyan; Karl-Henning Kalland; Marsha A Moses; Helga B Salvesen; Lars A Akslen Journal: BMC Cancer Date: 2012-05-06 Impact factor: 4.430